Company Description
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry.
In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry.
Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks.
It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians.
Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
| Country | United States |
| Founded | 1954 |
| IPO Date | Sep 20, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 9,450 |
| CEO | Jeffrey Simmons |
Contact Details
Address: 2500 Innovation Way Greenfield, Indiana 46140 United States | |
| Phone | 877 352 6261 |
| Website | elanco.com |
Stock Details
| Ticker Symbol | ELAN |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001739104 |
| CUSIP Number | 28414H103 |
| ISIN Number | US28414H1032 |
| Employer ID | 82-5497352 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey N. Simmons | President, Chief Executive Officer and Director |
| Todd S. Young J.D. | Executive Vice President and Chief Financial Officer |
| Dr. Ramiro Martin Cabral | Executive Vice President of Elanco International |
| Dr. Ellen de Brabander Ph.D. | Executive Vice President of Research, Development and Regulatory Affairs |
| Timothy J. Bettington | Executive Vice President of Corporate Strategy and Market Development |
| James M. Meer | Senior Vice President and Chief Accounting Officer |
| Chris Keeley | Senior Vice President and Chief Information Officer |
| David S. Kinard | Executive Vice President of Human Resources, Corporate Communications and Administration |
| Shiv O'Neill | Executive Vice President, General Counsel and Corporate Secretary |
| Larbi Van Lier | Senior Vice President of Asia |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 27, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 7, 2025 | SCHEDULE 13G/A | Filing |
| Feb 25, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G | Filing |
| Feb 4, 2025 | SCHEDULE 13G | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Nov 12, 2024 | 8-K | Current Report |